Successful human pregnancy requires the maternal immune system to recognize and tolerate the semi-allogeneic fetus. Myeloid-derived suppressor cells (MDSCs), which are capable of inhibiting T-cell responses, are highly increased in the early stages of pregnancy. Although recent reports indicate a role for MDSCs in fetal-maternal tolerance, little is known about the expansion of MDSCs during pregnancy. In the present study, we demonstrated that the trophoblast cell line HTR8/SVneo could instruct peripheral CD14
INTRODUCTION
The key events during early pregnancy are successful embryo implantation and the establishment of fetal-maternal tolerance 1 . There is a diverse population of maternal leukocytes that not only mediate the implantation and promotion of trophoblast differentiation but also regulate the maternal immune response to promote tolerance of the fetal semi-allograft. As major leukocyte subsets, CD14
1 myelomonocytic cells increase after embryo implantation and closely contact fetal trophoblast cells. Owing to their remarkable plasticity, cytokine production, and functional properties, different subtypes of maternal CD14
1 myelomonocytic cells perform multiple disparate functions during early pregnancy [2] [3] [4] [5] . Maternal CD14 1 myelomonocytic cells have gained increasing attention, as these cells play a multifaceted role during early pregnancy; however, the definition of new subsets and the contribution of each population to the immunological microenvironment of pregnancy are just beginning to emerge. CD14 1 HLA-DR 2/low cells, a subset of CD14 1 myelomonocytic cells, exhibit potent suppressive activity 6 , and these cells are monocytic myeloid-derived suppressor cells (MOMDSCs) 7, 8 , which have emerged as key immune modulators orchestrating lymphocyte responses. There is increasing interest in the role of MDSCs as tolerance-inducing cells during pregnancy 9, 10 . Although studies have suggested that isolated myeloid cells or MDSCs from the peripheral blood of pregnant women could efficiently suppress T-cell proliferation, information concerning the mechanisms governing MDSCs mobilization, particularly during the implantation and invasion of trophoblast cells, is lacking.
As key mediators, chemokines coordinate the complicated cellular migration or interactions between trophoblast cells and immunocytes at the maternal-fetal interface 11, 12 . As the first identified chemokine C-C motif ligand, CCL2 was markedly increased at the fetomaternal interface during blastocyst implantation 13 . This chemokine has been shown to mediate the local recruitment of CD14 1 myelomonocytic cells, T cells and natural killer (NK) cells into various tissues 14 . Notably, studies have shown that CCL2 also promotes the development of polarized Th2 responses and mediates immune tolerance 15, 16 . Although some studies have shown that both the existence of MDSCs and the increasing production of CCL2 significantly promote immunotolerance toward embryonic tissues, limited evidence is available concerning an association between MDSCs and CCL2 during the early stages of pregnancy. Trophoblast cells might be potential candidates for immunotolerance, as these cells recruit and activate CD14 1 myelomonocytic cells and, upon appropriate stimulation, produce CCL2 17 . Trophoblast cells educate and induce maternal leukocytes toward differentiation, thereby promoting a tolerogenic immune response to ensure a successful pregnancy [17] [18] [19] . Thus, the functional programs of CD14 1 myelomonocytic cells are probably activated and mobilized upon cross-talk with trophoblast cells.
To determine the role for trophoblast cells in the education of maternal CD14
1 myelomonocytic cells, the establishment of an in vitro coculture system is necessary. In the current study, the trophoblast cell line HTR8/SVneo 20, 21 and CD14 1 myelomonocytic cells, isolated from peripheral blood, were employed in a coculture system. We investigated the interaction between these cells for the potential expansion of CD14 1 HLA-DR 2/low cells and examined the role of CCL2 during this process.
MATERIALS AND METHODS
Donor recruitment and blood sample preparation A total of 21 healthy nonpregnant women and 13 healthy pregnant women at the early stages of pregnancy participated in the present study after providing consent in accordance with the Ethics Committee of Qilu Hospital. Peripheral blood was collected from pregnant (20-35 years of age), and nonpregnant females of similar age distributions served as controls. White blood cells (WBC) were obtained from these donors and used for cytometry analysis. In coculture experiments, PBMCs or other isolated cells were collected from healthy nonpregnant donors.
Reagents and antibodies
The fluorescently labeled anti-human mAbs against CD14-FITC, CD14-PE, HLA-DR-PE-Cy7, and CD4-APC and isotype antibodies used for flow cytometric analysis and the Annexin V/APC kit used for cell apoptosis analysis were obtained from Becton-Dickinson Biosciences (San Diego, CA, USA). Red blood cell (RBC) lysis buffer was purchased from BD Biosciences (San Diego, CA, USA). The CellTrace CFSE Cell Proliferation Kit for proliferation assays was obtained from Molecular Probes (Eugene, OR, USA). CD14 and CD4 Microbeads were obtained from Miltenyi Biotech (BergischGladbach, Germany). The anti-human CD3e mAb, antihuman CD28 mAb, mouse anti-human CCL2 neutralizing antibody and isotype antibodies were obtained from R&D Systems (Minneapolis, MN, USA). For western blot analysis, rabbit anti-human STAT3 and anti-human phosphor-STAT3 mAbs were purchased from Cell Signaling Technology (Boston, MA, USA), and the mouse anti-human b-actin mAb was purchased from Jingmei (Beijing, China).
Cell isolation and sorting
Peripheral blood mononuclear cells (PBMC) were isolated through centrifugation over Ficoll Histopaque-1077 gradients (Sigma-Aldrich, St. Louis, MO, USA) using the peripheral blood of healthy nonpregnant female volunteers. To isolate CD14
1 myelomonocytic cells, the PBMCs were suspended in MACS buffer (0.5% bovine serum albumin) and incubated with CD14 MicroBeads at 4uC for 15 minutes. The cell suspension was applied onto an MS separation column (Miltenyi Biotech, Bergisch Gladbach, Germany) attached to a magnetic field. After washing the column three times, the labeled CD14 1 myelomonocytic cells were collected according to manufacturers' instructions. To isolate CD4
1 T cells, PBMCs were purified using CD4 Microbeads and an MS separation column according to the manufacturers' instructions. The isolated CD14
1 myelomonocytic cells and CD4 1 T cells was.95% pure, assessed using flow cytometry. In some coculture experiments, CD14
1 myelomonocytic cells were sorted into CD14 1 HLA-DR 2/low cells and CD14 1 HLA-DR 1 cells using the BD Influx cell sorting system (BD Biosciences, San Diego, CA, USA). The purity of the cells was.98% after sorting.
Coculture system studies The trophoblast cell line HTR8/SVneo was a kind gift from Dr. Charles Graham (Queens University, Kingston, ON, Canada). These cells were acquired from human explant cultures obtained from the first trimester placenta and immortalized through transfection using a cDNA construct encoding the SV40 large T antigen 22 . These non-tumorigenic and metastatic cells are highly invasive in vitro and exhibit various markers of extravillous trophoblasts in situ 21, 22 . HTR8/ SVneo cells were seeded (1 mL/well, 5 3 10 5 /mL) onto a 6-well culture plate (BD Biosciences, Franklin Lakes, NJ, USA) and incubated for 4 hours to facilitate attachment. The CD14
1 myelomonocytic cells (1 mL, 1 3 10 6 /mL) were subsequently plated onto culture plates. In transwell coculture experiments, 0.4 mm transwell inserts (BD Biosciences, Franklin Lakes, NJ, USA) were used to separate CD14 1 myelomonocytic cells and HTR8/SVneo cells. CD14
1 myelomonocytic cells (1 mL, 1 3 10 extracts and cell-free supernatants were collected. In some experiments, 10 mg/mL anti-CCL2 neutralizing mAb was added to the coculture system for 40 hours, and then the cell-free supernatants and cells were collected.
Flow cytometric analysis
To detect the frequency of CD14 1 HLA-DR 2/low cells in peripheral WBC and coculture systems, whole-blood samples or further isolated cells were stained with fluorescently labeled Abs for 30 minutes in the dark at room temperature. To detect CD14
1 HLA-DR 2/low cells among WBC populations, 1 mL of RBC lysis buffer (BD Biosciences, San Diego, CA, USA) was added to a 200-mL aliquot of the peripheral blood sample for 10 minutes. Cell acquisition was performed using a FACSCalibur flow cytometer (BD Biosciences, San Diego, CA, USA), and the data were analyzed using the CellQuest software program (BD Biosciences, San Diego, CA, USA).
T-cell suppression assay
To detect the suppressive capability of MDSCs, CD14
1 myelomonocytic, CD14
1 HLA-DR
2/low
, or CD14 1 HLA-DR 1 cells (100 mL, 5 3 10 5 /mL) were sorted from the coculture system and subsequently cultured with isolated allogeneic CD4 1 T cells according to the methods described above for ''cell isolation and sorting'', using different CD14
1 cell/T-cell ratios (1:1, 1:2, and 1:4) in complete RPMI 1640 medium supplemented with 10% (v/v) FBS at 37uC for 40 hours. The autologous CD4 1 T cells were stained with CFSE according to the manufacturer's instructions, absorbed onto 96-well microtiter plates (BD Biosciences, Franklin Lakes, NJ, USA) and activated with aCD3 (1 mg/mL), aCD28 (5 mg/mL) and rhIL-2 (20 U/mL) for 3, 5, or 7 days. The CFSE signal of CD4 1 T cells was determined using a FACSCalibur flow cytometer.
Cytokine and chemokine analysis
The supernatant obtained from different culture groups was centrifuged at 2000g and immediately stored in liquid nitrogen until further use. The amount of human cytokines and chemokines, including CCL2, TGF-b, IL-4, IL-6, IL-8, and IL-10, in the coculture system and control supernatant was measured using an enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, UK) according to the manufacturer's instructions. All measurements were performed in triplicate to avoid technical errors and intra-assay variants.
Real-time quantitative RT-PCR (RTQ-PCR)
Total RNA was isolated from CD14 1 myelomonocytic, CD14
1 HLA-DR 2/low , and CD14 1 HLA-DR 1 cells sorted from the coculture system using the Qiagen RNeasy mini kit (Hilden, Germany) according to the manufacturer's instructions. RNA was reverse-transcribed to complementary DNA using RevertAid M-MuLV Reverse Transcriptase (Fermentas, Burlington, Ontario, Canada) with Oligo dT primers (Invitrogen, Carlsbad, CA, USA). IDO1, arginase-1 (ARG-1), IL-4Ra (CD124), NOS2, and COX2 were amplified through RTQ-PCR using the SYBR Green I (Bio-Rad, München, Germany) method in 10 mL reactions (5 mL of 2X TaqMan Master mix, 1 mL of each primer, 1 mL of cDNA, and 2 mL of H 2 O). All procedures were conducted according to the manufacturer's guidelines. RTQ-PCR was performed using a LightCycler 2.0 Instrument (Roche, Penzberg, Germany). The primer sequences are shown in Table 1 . The relative gene expression was normalized to GAPDH mRNA levels and expressed as a fold change for each relative gene reaction among the samples.
Western blotting
A total of 50 mg of protein from each treatment group was separated on an 8% sodium dodecyl sulfate polyacrylamide gel for STAT-3, pSTAT-3, and b-actin, respectively. The proteins were transferred to polyvinyl difluoride membranes (Millipore, Bedford, MA, USA), which were subsequently blocked and immunoblotted with the appropriate primary antibodies overnight at 4uC. The membranes were washed, and the bounded antibodies were visualized using peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology, CA, USA). The results were visualized through chemiluminescence detection using an ECL Kit (Millipore, Bedford, MA, USA) on an Image Station 4000 MM Pro (Carestream Health Inc., USA).
Statistical analysis
Prism 5.0 (GraphPad Software, CA, USA) was used for statistical analysis. We used the Shapiro-Wilk's test to analyze the normality of the data. When the data were normally distributed, we used a two-tailed Student's t-test and Pearson's test. Non-normally distributed data were analyzed using the MannWhitney U test. For all statistical tests, p values ,0.05 were considered statistically significant. The data from independent experiments are presented as the mean values 6 standard error of the mean (mean 6 SEM) for percentages. Figure 1A , the percentage of CD14
1 HLA-DR 2/low cells in circulating CD14 1 myelomonocytic cells among the total WBC population was significantly higher in pregnant women during early pregnancy (3.586 6 0.211%) as compared with non-pregnant female volunteers (2.295 6 0.136%) (p ,0.001). However, no significant difference (p 5 0.4353) in the percentage of CD14 1 myelomonocytic cells among the total WBC population was observed ( Figure 1B) .
Increasing attention has been paid to the complex immunoregulatory function of trophoblast cells in close contact with immunocytes. Therefore, we investigated whether circulating CD14 Figure 1A and B). To eliminate the downregulation of HLA-DR, potentially occurring during the early apoptosis stage of CD14 1 myelomonocytic cells, we examined the apoptosis of CD14 1 myelomonocytic cells using a coculture system. The data indicated that the percentage of apoptotic CD14
1 myelomonocytic cells in the coculture system was less than 6.5% (Supplementary Figure 2A) . In summary, HTR8/SVneo cells were probably involved in the expansion of CD14 1 HLA-DR 2/low cells.
HLA-DR
2/low cells from coculture system are MDSCs that inhibit autologous T-cell proliferation To determine whether the CD14 1 myelomonocytic cells in coculture system possess MDSC functions, we examined the ability of these cells to inhibit CD4
1 T-cell proliferation activated via anti-CD3/CD28 mAbs as described in Materials and Methods section. CFSE-labeled autologous CD4
1 T cells were used as responders. As shown in Figure 2A , the percentage of expanding CD4
1 T cells did not show significant changes in various groups in the first 5 days. However, only CD14
1 myelomonocytic cells isolated from coculture system lead to significant CD4
1 T cell suppression after day 7. By contrast, CD14
1 myelomonocytic cells alone showed no inhibitory effect. Thus, these data suggested that trophoblast cells might educate circulating CD14
1 myelomonocytic cells as suppressor cells with inhibitory activity on T-cell proliferation.
To directly assess whether CD14 1
2/low cells generated in vitro after colculture with CD14 1 myelomonocytic cells with HTR8/SVneo cells could indeed exert the suppressor functions of MO-MDSCs, as previously reported in other nonpregnancy systems 8 . CD14
1 HLA-DR 2/low cells sorted from coculture systems were added to activated autologous CD4 1 T cells at different ratios, and proliferation was analyzed. As shown in Figure 2B , CD14
1 HLA-DR 2/low cells efficiently inhibited autologous CD4
1 T-cell proliferation, with maximal inhibition at a 1:1 effector-target ratio. Therefore, the cells were cocultured at ratios of 1:1 to dissect the suppressive mechanism in the following experiments. As expected, control CD14
1 HLA-DR 1 myelomonocytic cells sorted from coculture systems failed to suppress the proliferation of the responding autologous CD4
1 T cells at any ratio. Thus, the main population of suppressor CD14
1 myelomonocytic cells in coculture system was CD14
1 HLA-DR 2/low cells. The gating strategies, including representative dot plots, for all flow cytometric and sorting experiments are shown in supplementary information (Supplementary Figure 1C and Figure 2B ).
To determine whether CD14 1 HLA-DR 2/low cells from coculture systems were MDSCs, we analyzed the expression of several typical MDSC-associated mediators of suppressive function, including IDO1, arginase-1 (ARG-1), IL-4Ra (CD124), NOS2, and COX2, using RTQ-PCR. As expected, the results indicated that CD14
1 HLA-DR 2/low cells expressed high levels of IDO1, ARG-1, and COX2 ( Figure 2C) MDSCs from circulating CD14 1 myelomonocytic cells, we investigated CCL2 levels in the coculture system using ELISA. As shown in Figure 3 , neither CD14
1 myelomonocytic cells nor HTR8/SVneo cells secreted high levels of CCL2, whereas CCL2 levels increased.100-fold upon coculture for 40 hours ( Figure 3A) . To ascertain whether the elevated levels of CCL2 and expansion of CD14 1 HLA-DR 2/low cells in coculture were specific for trophoblast cells, we also utilized HUVECs and the endothelial cell line ECV304 in coculture with CD14 1 myelomonocytic cells. Flow cytometric analysis and ELISA detection showed that neither of these cell lines was involved in the expansion of CD14 1 HLA-DR 2/low cells. Furthermore, there was no significant difference between the levels of CCL2 in these coculture systems and CD14
1 myelomonocytic cell culture alone (Supplementary Figure 3) . Furthermore, we examined the expression of cytokines, including IL-4, IL-8, IL-6, IL-10, and TGF-b, which also play an important role in contributing to fetal-maternal tolerance during the first trimester of pregnancy. As shown in Figure 3A , the level of secreted TGF-b was slightly increased in the supernatants of coculture systems, but no significant changes in the levels of other cytokines were observed.
We utilized transwell cultures to assess whether the increased CCL2 secretion depended on cell-cell contact. As shown in Figure 3B , there was no significant increase in CCL2 levels when
CD14
1 myelomonocytic cells were cultured in transwell cultures with HTR8/SVneo cells, shown in the figure as CD14 1 / HTR8 (TW). These results showed that the ability of coculture systems to promote CCL2 secretion depended on cross-talk between CD14
1 myelomonocytic cells and HTR8/SVneo cells. We also determined the source of CCL2 secretion in the supernatant of coculture systems. For this purpose, we sorted CD14 1 myelomonocytic cells and HTR8/SVneo cells from 1 :CD4 1 ratio) for 3, 5, and 7 days to assess the inhibition of T-cell coculture systems, and the RTQ-PCR results showed that only CD14 1 myelomonocytic cells expressed high levels of CCL2 ( Figure 3C ). Further analysis indicated that there was no substantial difference in the CCL2 expression between CD14 1 HLA-DR 2/low and CD14 1 HLA-DR 1 cells (data not shown). Furthermore, no CCL2 mRNA could be detected in HTR8/SVneo cells. These data indicate that the primary source of CCL2 is CD14 1 myelomonocytic cells, and trophoblast cells promote this process in a cell-to-cell contact manner. To further examine this effect, we also examined the changes in CCL2 secretion in the supernatant. As shown in Figure3 D, there was no visible increase until 6 hours, and the growth rate stabilized after a significant peak at 20 hours.
HTR8/SVneo cells expand CD14
1 HLA-DR 2/low MDSCs via CCL2 Increased evidence has shown that CCL2 is gradually over expressed in the tumor site, and this expression is involved in the progression of cancer. Host MDSCs cocultured with tumor cells in the tumor microenvironment also closely connected with CCL2 23 . Given these correlative data, the substantial changes in CCL2 expression in the coculture system indicated that this chemokine was probably an important mediator of the induction of HTR8/SVneo cells on CD14 
HLA-DR
2/low MO-MDSCs. To explore the potential role of CCL2 in the experimental setting used in the present study, an anti-CCL2 neutralizing mAb (10 mg/mL) was added to the media of the coculture system at the beginning, and the isotype antibody (10 mg/ mL) also served as a negative control. We observed that CD14 1 myelomonocytic cells obtained from coculture using isotype antibodies or no antibodies showed a similar frequency of CD14
1 HLA-DR 2/low MDSCs. By contrast, when anti-CCL2 was added to the media, a significant decrease in the percentage of CD14 1 HLA-DR 2/low MDSCs was observed ( Figure 4A ). Suppression assay showed that the ability of CD14 1 myelomonocytic cells to suppress CD4 1 T-cell expansion was significantly decreased when CCL2 was neutralized; however, the isotype antibody had no effect ( Figure 4B ). To further analyze whether the neutralization of CCL2 influences the inhibitory function of CD14 1 HLA-DR 2/low MDSCs, we sorted these cells from different groups (with anti-CCL2, isotype antibody, or no antibody), and suppression assay showed that there was no significant difference in the capacity of these cells to suppress T-cell expansion ( Figure 4B ). These results showed that the suppression ability of CD14 1 myelomonocytic cells decreased, probably reflecting a reduction in the percentage of CD14 1
2/low MDSCs in coculture systems. We further explored the expression of several MDSC-associated mediators in CD14 1 myelomonocytic cells from different groups. As shown in Figure 4C , compared with isotype antibody or no antibody groups, only ARG-1 was significantly decreased when treated with anti-CCL2. It is unclear whether this reduction reflected a decrease in the number of CD14 
2/low MDSCs. In addition, CCL2 also regulates the expression of ARG-1 in MDSCs.
CD14
1 HLA-DR 2/low cells express STAT3 and pSTAT3 associated with increased CCL2 A previous study showed that STAT3 signaling plays an important role in CD14
1 HLA-DR 2/low MDSCs expansion 24 . We examined whether STAT3 signaling was also involved in the expansion of CD14 1 HLA-DR 2/low MDSCs through crosstalk between CD14
1 myelomonocytic cells and trophoblast cells and whether CCL2 mediates this process. CD14
1 myelomonocytic cells were sorted from different groups, and the expression of STAT3 was detected through western blot analysis. After culturing for 40 hours, we observed statistically higher STAT3 protein expression in CD14 1 myelomonocytic cells from coculture systems (MH) compared with CD14 1 myelomonocytic cells cultured alone (M) ( Figure 5A ). In addition, we also detected the STAT3 expression in sorted CD14 1 
HLA-DR
2/low MDSCs and CD14 1 HLA-DR 1 myelomonocytic cells. Figure 5B shows the increased expression of STAT3 protein in CD14 1 HLA-DR 2/low MDSCs compared with other cells.
To determine the role of CCL2 in regulating STAT3 signaling, the experiments described in the previous section were performed using CD14 1 myelomonocytic cells in an HTR8 coculture system in the absence of CCL2. Accordingly, the STAT3 protein levels were detected through western blotting. As shown in Figure 5A , we observed significantly lower levels of STAT3 expression in a coculture system in the absence of functional CCL2 (MH anti-CCL2 group). To further confirm whether CCL2 exerts an effect on MDSC differentiation via STAT3 signaling, we sorted CD14 1 myeloid cells from the coculture system at different time points, and phosphorylated STAT3 (pSTAT3) was detected through western blotting. We observed low levels of pSTAT3 protein expression in CD14
1 myelomonocytic cells as early as 2 hours after coculture with HTR8; pSTAT3 expression was sustained, increasing at subsequent time points and peaking after 8 hours ( Figure 5C ). In contrast, the neutralization of CCL2 suppressed pSTAT3 detection until 6 hours, and this expression was subsequently maintained at a lower level ( Figure 5D ). In conclusion, these findings demonstrated HLA-DR 2/low MDSCs. Anti-CCL2 neutralizing mAb (10 mg/mL) and the isotype antibody (10 mg/mL) were added to the media of coculture systems as described in Figure. that STAT3 signaling was involved in the expansion of CD14 1 HLA-DR 2/low MDSCs, and this effect was partially influenced through CCL2.
DISCUSSION
In the present study, we utilized the well-characterized human trophoblast cell line HTR8/SVneo to demonstrate the notable role of these cells in educating CD14
1 myelomonocytic cells, resulting in the expansion of immunosuppressive CD14
1 HLA-DR 2/low monocytic MDSCs (MO-MDSCs). To our knowledge, this study presents novel findings suggesting that CD14 1 HLA-DR 2/low MDSCs could be induced using a unique maternal-fetal coculture system, and a positive regulatory loop might exist between trophoblast cells and maternal immune cell subsets to promote to the induction of maternal-fetal immunotolerance.
During the early stages of pregnancy, numerous maternal immune cells, including CD14
1 myelomonocytic cells, NK cells, and Tregs, should tolerate invading trophoblast cells to facilitate adequate placental growth and development for the success of pregnancy 25, 26 . Reflecting remarkable plasticity, CD14
1 myelomonocytic cells efficiently respond to various environmental stimuli, particularly the semi-allograft, which might induce the differentiation of these cells in a tissue-specific manner for immune regulation and host defense responses 2, [27] [28] [29] . Studies have shown that CD14 1 myelomonocytic cells, which intimately contact the embryo allograft, displayed a unique ability to promote immunotolerance via the induction of Tregs 2 . Previous studies have shown that decidual CD14 1 myelomonocytic cells express markers associated with alternative activation; 30 however, by contrast, a recent report suggests that there are two unique CD14
1 myelomonocytic cell subtypes in human decidua, which secrete both anti-inflammatory and proinflammatory cytokines 4 . Thus, the diverse inhibitory and stimulatory roles of different subtypes of CD14 1 myelomonocytic cells imply that the fate determination of these subtypes might be an important mechanism underlying the development of a unique immune microenvironment at the maternal-fetal interface. In this context, we identified an increase in a subpopulation of CD14 1 myelomonocytic cells with low or no expression of HLA-DR in the PBMCs of pregnant women during early pregnancy, and these cells can be induced through HTR8/SVneo cells in vitro (Figure 1) . Here, we proposed that increased CD14 1 myelomonocytic cells sorted from coculture system using an anti-CCL2 neutralizing mAb was detected at the same time points as indicated in (C). All respective bands densities were normalized to b-actin. All images represent nine independent experiments, and all data are shown as the means 6 SEM. **p ,0.001.
various maternal immune cells, particularly CD14
1 myelomonocytic cells, interactive cross-talk between the cellular compartments is critical for maternal-fetal tolerance [17] [18] [19] 31 . Previous studies have shown that trophoblast cells express a wide range of chemokines and cytokines, which induce CD14 1 myelomonocytic cell differentiation into special subtypes with higher levels of IL10 and increased capacity for phagocytosis 31, 32 . We have performed several functional analyses, revealing that HTR8/SVneo cell-induced CD14
1 HLA-DR 2/low cells effectively inhibited the expansion of CD3/ CD28-activated autologous CD4
1 T cells (Figure 2 ). Supporting these data, CD14
1 HLA-DR 2/low cells have recently been identified as a new subpopulation of MDSCs in melanoma patients 6 . The robust inhibitory capacity of MDSCs has generated significant interest in the generation and activation of these specialized immunocytes. Human MDSCs can be divided into monocytic (CD14 1 , MO-MDSCs) and granulocytic (CD14
2

CD15
1 , GR-MDSCs) cells based on cell surface markers. Until recently, the different roles of the two MDSC subpopulations have been poorly understood 33 . In human pregnancy, myeloid cells and highly increased granulocytic-MDSCs (GR-MDSCs) isolated from peripheral blood are more strongly inhibitory toward T-cell proliferation 9, 10 . By contrast with the present study, these authors observed unchanged numbers of peripheral MO-MDSCs in normal pregnant female; 10 however, it was not determined whether MDSCs contribute to maternalfetal tolerance during implantation. These studies did not detect changes in MO-MDSCs numbers, probably reflecting the analysis of the abundance of CD14 1 HLA-DR 2/low cells in all peripheral leukocytes, and an analysis of the percentage of the peripheral CD14 1 myelomonocytic cells would be more reasonable. Additionally, it has been proposed that MDSCs exert suppressive activity through an extensive range of mechanisms both in vitro and in vivo. Several key molecules, such as IDO1, arginase-1 (ARG-1), IL4Ra, NOS2, and COX2, mediate these suppressive modalities 33 . We analyzed the expression of these key molecules and observed that the levels of IDO1, ARG-1, and COX2 expression in CD14 1 HLA-DR 2/low cells in coculture were significantly higher compared with control. These data also implied that HTR8/SVneo cells mediate immunoregulation via the induction of CD14 1 HLA-DR 2/low MO-MDSCs and upregulate IDO1, ARG-1, and COX2 expression in these cells.
The data obtained from in vitro studies showed that various cytokine cocktails could induce MDSC expansion from myeloid cells 34 . In the present study, a number of associated cytokines were assayed. Compared with other modulatory cytokines, CCL2 expression is profoundly upregulated in CD14 1 myelomonocytic cells after culturing with HTR8/ SVneo cells, depending on cell-cell contact. As a pleiotropic CC chemokine, CCL2 plays an important role in the migration and differentiation of lymphoid cells 14, 15, 35 . In the reproductive system, CCL2 is secreted from decidual, endometrial, and myometrial cells, and this chemokine is elevated on the first day of pregnancy in the mouse uterus 13 . Recombinant human CCL2 promotes Th2 cytokine production and inhibits the secretion of Th1 cytokines 36 . Based on the abundant expression of CCL2 at the fetomaternal interface during trophoblast cell invasion, and the efficient recruitment and education of lymphoid cells for the establishment of fetomaternal immune tolerance, we speculated that the sharp increase in CCL2 expression could play an important mediator role in the cross-talk between HTR8/SVneo cells and CD14
1 myelomonocytic cells. Indeed, the results of the present study provide clear evidence that CCL2 plays a remarkable role in HTR8/ SVneo cell-induced CD14
1 HLA-DR 2/low MDSCs (Figure 4 ). These data are important as it remains unclear whether CCL2 participates in the induction of MDSCs. The ability of CCL2 to promote CD14
1 HLA-DR 2/low MDSC differentiation from peripheral CD14
1 myelomonocytic cells is a positive regulatory loop. After secreting considerable amounts of CCL2 at the maternal-fetal interface, CD14
1 myelomonocytic cells attract and stimulate themselves in an autocrine manner, leading to the expanding of MDSCs and contributing to maternal-fetal tolerance.
Previous studies have established an important role for signal transducer and activator of transcription 3 (STAT3) in MDSC expansion in mice 37, 38 . These results were further supported by an in vivo study employing the tyrosine kinase inhibitor sunitinib, which inhibited MDSC proliferation in tumorbearing mice via the inhibition of the STAT3 signaling pathway in myeloid cells 39 . Recently, an association has been demonstrated between increased STAT3/pSTAT3 activity and MDSC expansion in melanoma patients 6 . Consistently, these results reveal that both STAT3 and pSTAT3 expression in CD14 1 myelomonocytic cells, particularly in CD14 1 HLA-DR
2/low
MDSCs, are upregulated through coculture with HTR8/ SVneo cells. We also showed that an anti-CCL2 neutralizing antibody remarkably inhibits STAT3 and pSTAT3 expression ( Figure 5 ). This finding indicates that STAT3 signaling is closely associated with the levels of CCL2 expression during HTR8/SVneo cell-induced MDSC expansion. Notably, anti-CCL2 neutralizing antibodies diminish the frequency of CD14 1 HLA-DR 2/low MDSCs and downregulate the expression of ARG-1 in coculture ( Figure 4C ). However, there is no significant difference in the capacity to inhibit T-cell proliferation ( Figure 4B ). Thus, we inferred that the soluble mediator CCL2 plays a substantial role in the induction of CD14
1 HLA-DR 2/low MDSCs, but there are probably other molecules involved in the inhibitory activities of CD14 1 HLA-DR 2/low MDSCs. Further research is required to reveal this potential pathway.
In conclusion, the findings presented here provide substantial evidence for a better understanding of the molecular and cellular mechanisms involved in the establishment and maintenance of maternal-fetal tolerance during the early stages of pregnancy in humans. Indeed, the cross-talk and feedback between the trophoblast HTR8/SVneo cells and CD14
1 myelomonocytic cells might play a crucial and positive regulatory role in the expansion of CD14 1 HLA-DR 2/low MDSCs, and this effect is mediated through CCL2. However, the role of MDSCs in the establishment and maintenance of maternal-fetal tolerance has not been clarified. By contrast, the immunocytemediated suppression of the maternal immune system also increases the risk of infection during pregnancy. For instance, this suppression might increase the susceptibility to toxoplasmosis and listeriosis and increase mortality rates from influenza and varicella infections. It seems paradoxical to be both tolerant of the embryo and defensive against infection. However, how suppressive immunocytes precisely regulate the maternal immune system in response to various pathological and physiological circumstances requires further study.
Overall, these findings might provide a potential alternative pathway to obtain a better understanding of the maternal immunomodulatory mechanism during pregnancy. Furthermore, the elucidation of the molecular and cellular mechanisms of expanding MDSCs in the establishment of immune tolerance might not only provide a new strategy to overcome immunosuppression mediated through MDSCs in the therapy of cancer patients but also provide new opportunities for inducing tolerance in transplantation.
